NEU Insider Trading

Insider Ownership Percentage: 13.29%
Insider Buying (Last 12 Months): A$198,216.38
Insider Selling (Last 12 Months): A$0.00

Neuren Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Neuren Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neuren Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for NEU up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Neuren Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2024Joseph(Joe) BasileInsiderBuy6,406A$15.73A$100,766.38
6/11/2024Joseph(Joe) BasileInsiderBuy5,000A$19.49A$97,450.00
9/13/2023Joseph(Joe) BasileInsiderBuy5,000A$11.99A$59,950.00
6/14/2023Trevor ScottInsiderSell1,175,000A$13.00A$15,275,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Neuren Pharmaceuticals (ASX:NEU)

17.85% of Neuren Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Neuren Pharmaceuticals logo
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Read More on Neuren Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

57,935 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.13

Who are the company insiders with the largest holdings of Neuren Pharmaceuticals?

Neuren Pharmaceuticals' top insider investors include:
  1. Joseph(Joe) Basile (Insider)
  2. Trevor Scott (Insider)
Learn More about top insider investors at Neuren Pharmaceuticals.